S-1/A: Scientific Industries Files S-1/A for Resale of 3.1 Million Shares Amidst Ongoing Losses and Going Concern Warning

Scientific Industries, Inc. has filed an S-1/A registration statement for the resale of up to 3.1 million shares of common stock by selling stockholders, while reporting continued net losses and acknowledging substantial doubt about its ability to continue as a going concern.

Summary

• The S-1/A filing registers 3,100,000 shares of common stock for resale by selling stockholders, including 1,050,000 shares issued in a private placement on April 18, 2025, 500,000 shares issuable upon exercise of pre-funded warrants, and 1,550,000 shares issuable upon exercise of warrants.
• The company will not receive any proceeds from the sale of shares by selling stockholders, but will receive proceeds from the exercise of warrants, which will be used for ordinary course working capital needs.
• Scientific Industries operates in two segments: Benchtop Laboratory Equipment (stable and profitable) and Bioprocessing Systems (focus for growth, but currently incurring significant expenses).
• The company reported a net loss of $1,778,500 for the three months ended March 31, 2025, an improvement from a $2,051,600 loss for the same period in 2024, primarily due to cost-cutting initiatives in the Bioprocessing Systems Operations.
• Net revenues for the three months ended March 31, 2025, decreased by 3.1% to $2,406,500 from $2,483,500 in the prior year, driven by a $182,600 decrease in Bioprocessing Systems revenues, partially offset by a $105,600 increase in Benchtop Laboratory Equipment sales.
• For the year ended December 31, 2024, the company reported a net loss of $6,445,400, a reduction from $9,086,500 in 2023, mainly due to decreased operating costs in the Bioprocessing Systems segment.
• Annual net revenues for 2024 decreased by 3.6% to $10,712,600 from $11,111,500 in 2023, with Bioprocessing Systems revenues increasing by $323,700 (due to the new DOTS MPS product) and Benchtop Laboratory Equipment revenues decreasing by $722,600.
• The decrease in Benchtop Laboratory Equipment revenue was primarily due to reduced Torbal division sales, particularly VIVID pill counters, impacted by new regulations (DIR fees) affecting independent pharmacies, and a 4% decrease in Genie division sales due to overall market softness.
• As of March 31, 2025, the company had an accumulated deficit of $35,709,000 and negative cash flows from operations of $1,331,100 for the three months ended March 31, 2025.
• The company's auditors included an explanatory paragraph in their report regarding substantial doubt about the company's ability to continue as a going concern.

Sentiment

Score: 2

Explanation: The sentiment is overwhelmingly negative due to the explicit 'going concern' warning, persistent net losses, declining revenues in core segments, and the stated need for additional capital without committed sources. While cost-cutting has reduced losses, the underlying financial instability and market challenges present significant concerns for investors.

Positives

• Net loss improved for both the three months ended March 31, 2025 ($1,778,500) compared to March 31, 2024 ($2,051,600), and for the year ended December 31, 2024 ($6,445,400) compared to December 31, 2023 ($9,086,500), primarily due to cost-cutting initiatives.
• Gross profit percentage for the three months ended March 31, 2025, increased slightly to 42.2% from 41.9% in the prior year, driven by higher gross margin in the Bioprocessing Systems Operations.
• General and administrative expenses decreased by 17.8% ($270,500) for Q1 2025 and 11.0% ($595,200) for FY 2024 due to reduced employee-related costs and non-cash stock-based compensation in the Bioprocessing Systems Operations.
• Selling expenses decreased by 32.3% ($1,734,800) for FY 2024 due to reduced non-cash stock-based compensation and a reduction of sales and marketing employees in the Bioprocessing Systems Operations.
• Research and development expenses decreased by 8.3% ($58,700) for Q1 2025 and 18.5% ($660,100) for FY 2024 due to cost reductions in Bioprocessing Systems and completion of a new VIVID automated pill counter.
• Bioprocessing Systems Operations saw an increase in net revenues of approximately $323,700 in 2024, principally from the new DOTS MPS product launch.
• Benchtop Laboratory Equipment Operations showed an increase of $105,600 in revenues for the three months ended March 31, 2025.

Negatives

• The company continues to incur significant net losses, with an accumulated deficit of $35,709,000 as of March 31, 2025.
• Net revenues decreased by 3.1% for the three months ended March 31, 2025, and by 3.6% for the year ended December 31, 2024.
• The Bioprocessing Systems Operations experienced a $182,600 decrease in revenues for the three months ended March 31, 2025.
• The gross profit percentage for the year ended December 31, 2024, decreased to 44.2% from 45.9% in 2023, primarily due to increased cost of materials, labor, and fixed overhead for the Benchtop Laboratory Equipment Operations.
• Cash and cash equivalents decreased by $208,200 to $587,900 as of December 31, 2024, from $796,100 as of December 31, 2023.
• The company generated negative cash flows from operations of $1,331,100 for the three months ended March 31, 2025, and $3,683,500 for the year ended December 31, 2024.
• The company's operating cash flow, cash on hand, and line of credit are not sufficient to fund cash requirements over the next twelve months, raising substantial doubt about its ability to continue as a going concern.
• Sales of the Torbal division, including VIVID brand products, decreased significantly in 2024 due to new regulations (DIR fees) impacting independent pharmacies.
• The Genie division sales decreased by approximately 4% in 2024 due to overall market softness in demand for laboratory equipment.
• One product, the Vortex-Genie 2 Mixer, accounts for a substantial portion of revenues (approximately 34% of total net revenues for Q1 2025, 33% for FY 2024, and 32% for FY 2023).

Risks

• Limited financial resources and the potential need to raise additional funding, with no committed external source of funds.
• Inability to raise additional capital on acceptable terms could force delays, reductions, or elimination of product development or commercialization efforts.
• Future funding requirements are dependent on various factors, including product candidate scope, collaborations, number of product candidates, sales and marketing costs, and intellectual property costs.
• Raising additional capital through equity sales may dilute existing stockholders' ownership interests, and debt financing may impose restrictive covenants.
• A history of net losses and the expectation of continued operating losses for the foreseeable future, particularly due to expenses related to the Bioprocessing Systems operations.
• Failure to maintain proper and effective internal control over financial reporting could impair the ability to produce accurate and timely financial statements.
• A limited public market for Common Stock on the Over-the-Counter Bulletin Board, with historical thin trading and high price volatility, which may impair value and ability to raise capital.
• The commercial success of bioprocessing products largely depends on attaining significant market acceptance, which is uncertain in a relatively new and rapidly innovating market.
• Inability to obtain and maintain patent and other intellectual property protection for new bioprocessing products could allow competitors to develop similar products.
• Inadequate protection of trademarks and trade names could impede name recognition and adversely affect business.
• Loss of key management personnel, including Helena Santos (CEO/CFO), Robert Nichols (Genie President), Karl Nowosielski (Torbal President), Daniel Donadille (Bioprocessing CEO/President), or John A. Moore (Chairman), could harm business strategy execution.
• Reliance on highly skilled personnel and intense competition for qualified employees in the biopharmaceutical industry.
• Heavy dependence on international operations, particularly the Bioprocessing Systems Operations in Germany, which poses inherent risks in internal controls and is subject to differing laws and regulations.
• Inability to successfully manage any experienced growth, which would strain management and administrative, operational, and financial resources.
• Growth strategy is based on assumptions about the bioprocessing market (estimated TAM $26 billion, SAM $2.1 billion) that may prove incorrect, potentially impacting future product sales and market size.
• Dependence on major customers, with two customers accounting for 10% or more of total revenue for Q1 2025, and top three Benchtop Laboratory Equipment customers accounting for 24% and 18% of segment sales in 2024 and 2023, respectively.
• One benchtop laboratory equipment product, the Vortex-Genie 2 Mixer, accounts for a substantial portion of revenues, leading to dependence on a limited product portfolio.
• The company is a small participant in highly competitive industries, facing substantially larger competitors with greater financial, production, and marketing resources.
• Ability to grow and compete effectively depends on developing and marketing new products, with no assurance of success or distributor inclusion.
• Heavy reliance on distributors and their catalogs to market the majority of Benchtop Laboratory Equipment Genie products, with long lead times for new product inclusion.
• Bioprocessing products are complex, have taken longer to develop than anticipated, and are subject to beta testing and adoption by end users, which could cause further delays.
• Exposure to foreign exchange rate risk (transactional and translational), particularly between the U.S. dollar and the Euro, which may negatively affect financial performance.
• Subject to general economic, political, and social factors, including customer funding availability (e.g., government grants), global economic slowdowns, and tariffs.
• Higher material and transportation costs could negatively impact future gross margins if not passed on to customers.
• Heavy dependence on outside suppliers for components, reliance on a few suppliers, long lead times, and risks related to overseas production.
• Limited patent protection for most Benchtop Laboratory Equipment products, making the company vulnerable to competitive products with similar specifications.
• No anticipated declaration or payment of cash dividends for the foreseeable future, limiting stockholder returns to stock appreciation.

Future Outlook

The company expects to continue incurring operating losses for the foreseeable future as expenses related to the growth and expansion of its Bioprocessing Systems operations are anticipated to exceed revenues. The ability to become profitable depends on generating additional revenue and profits from the Bioprocessing Systems operations. The company believes there are greater growth opportunities in the Bioprocessing Systems segment, part of a large and expanding synthetic biology market, and is concentrating on its expansion, new product development, and commercialization strategy, including the recent launch of the Multi-Parameter Sensor. Future funding requirements are substantial and depend on the scope and success of product development and commercialization efforts.

Management Comments

• Management believes there are greater growth opportunities in the Bioprocessing Systems segment, as part of a large and expanding synthetic biology market sector worldwide.
• Management has concentrated on expansion of the Bioprocessing Systems segment and development of new products and technologies, and taking steps towards establishing a commercialization strategy of these products.
• Management has developed a strategic plan to secure additional capital resources, which may include capital from management and significant shareholders, third-party equity and/or debt financing, and exploring the sale of certain assets, but cannot provide any assurances of success.

Industry Context

Scientific Industries operates in two distinct but related industries: the mature and highly competitive Benchtop Laboratory Equipment industry and the relatively new, rapidly innovating bioprocessing products industry, which is part of the larger synthetic biology market. In the Benchtop Laboratory Equipment segment, the company is a small participant facing significantly larger competitors, with its principal product, the Vortex-Genie 2 Mixer, accounting for a substantial portion of segment sales. The bioprocessing segment, while a focus for growth and innovation with products like smart sensors and software analytics, is still in a start-up phase and also faces dominance by larger companies. The company's strategy involves leveraging the stable Benchtop segment to fund growth in the higher-potential Bioprocessing sector, but this involves significant investment and market acceptance challenges.

Comparison to Industry Standards

• The company is a small participant in the Benchtop Laboratory Equipment industry, with annual sales significantly lower than many competitors.
• The Benchtop Laboratory Equipment industry is described as highly competitive and mature, with constant new entrants, including those offering products imported from China, which the company cannot compete with on price.
• The Torbal line of products also faces significant competition from well-known brands.
• The Bioprocessing Systems operations is a participant in the laboratory-scale sector of the larger bioprocessing products industry, which is dominated by several significantly larger companies.

Corporate Governance

Stakeholder Impact

• Shareholders: Face potential dilution from future capital raises, continued stock price volatility due to thin trading, and no anticipated cash dividends in the foreseeable future. The going concern warning indicates significant risk to investment value.
• Employees: The company has implemented a reduction in force in the Bioprocessing Systems Operations, impacting employee-related costs. Future growth in the bioprocessing sector will require hiring additional qualified personnel.
• Customers: The company's ability to deliver new bioprocessing products depends on successful development and market acceptance. Reduced sales of certain Benchtop Laboratory Equipment products (e.g., VIVID pill counters) due to external factors like regulatory changes can impact customer access or product availability.
• Suppliers: The company is heavily dependent on outside suppliers for components, with reliance on a few suppliers and overseas production, posing risks of supply shortages and increased costs.
• Creditors: The going concern warning and the need for additional funding indicate potential challenges in meeting financial obligations without securing new capital.

Next Steps

• Continue to invest substantial capital into product development and commercialization programs, principally for the bioprocessing sector.
• Establish and execute a commercialization strategy for bioprocessing products, including the DOTS software platform and Multi-Parameter Sensor.
• Seek additional funding through public or private equity offerings, debt financings, collaborations, licensing arrangements, or product line divestitures to address liquidity shortfalls.
• Expand facilities, augment operational, financial, and management systems, and hire and train additional qualified personnel to manage anticipated growth in the bioprocessing sector.
• Continue efforts to develop and market new Benchtop Laboratory Equipment products to increase revenues and reduce dependence on the Vortex-Genie 2 Mixer.

Key Dates

Recommendation

Keywords

SEC filing, S-1/A, Scientific Industries, SCND, common stock, private placement, warrants, bioprocessing systems, laboratory equipment, financial results, net loss, revenue, going concern, capital raise, risk factors, corporate governance, intellectual property, market acceptance, supply chain